Table 4.
Predictors of SVR among patients with history of HCC and without prior liver transplant.
| HCC, all genotypes (n = 426) |
HCC, genotype 1 HCV (n = 344) |
|||||
|---|---|---|---|---|---|---|
| AOR† | 95% (CI) | p value | AOR† | 95% (CI) | p value | |
| Age | 0.98 | 0.92, 1.03 | 0.42 | 0.96 | 0.90, 1.02 | 0.24 |
| Race/Ethnicity | ||||||
| White, non-Hispanic | 1 | 1 | 1 | 1 | 1 | 1 |
| Black, non-Hispanic | 0.66 | 0.35, 1.23 | 0.19 | 0.49 | 0.24, 0.97 | 0.04 |
| Hispanic | 0.51 | 0.18, 1.43 | 0.20 | 0.30 | 0.09, 1.00 | 0.05 |
| Asian, Pacific Islander, American Indian | 0.90 | 0.17, 4.66 | 0.90 | 0.59 | 0.11, 3.30 | 0.55 |
| Missing | 1.41 | 0.53, 3.78 | 0.49 | 1.41 | 0.42, 4.73 | 0.57 |
| Alcohol use disorder | 0.66 | 0.39, 1.11 | 0.12 | 0.69 | 0.38, 1.26 | 0.23 |
| Diabetes | 0.64 | 0.38, 1.08 | 0.09 | 0.64 | 0.35, 1.18 | 0.16 |
| Genotype | ||||||
| 1 | 1 | 1 | 1 | n.a. | n.a. | n.a. |
| 2 | 0.43 | 0.16, 1.15 | 0.09 | n.a. | n.a. | n.a. |
| 3 | 0.19 | 0.10, 0.41 | < 0.001 | n.a. | n.a. | n.a. |
| 4 | 0.26 | 0.01, 5.01 | 0.37 | n.a. | n.a. | n.a. |
| Antiviral regimen | ||||||
| LDV/SOF | n.a. | n.a. | n.a. | 1 | 1 | 1 |
| LDV/SOF + ribavirin | n.a. | n.a. | n.a. | 1.07 | 0.58, 1.95 | 0.83 |
| PrOD | n.a. | n.a. | n.a. | - | - | - |
| PrOD + ribavirin | n.a. | n.a. | n.a. | 10.07 | 1.28, 79.3 | 0.028 |
| Baseline HCV RNA >6 million IU/ml | 0.55 | 0.24, 1.24 | 0.15 | 0.55 | 0.24, 1.24 | 0.15 |
| FIB-4 >3.25 | 0.59 | 0.30, 1.16 | 0.12 | 0.76 | 0.34, 1.67 | 0.49 |
| Platelet count <100,000/μl | 0.85 | 0.47, 1.55 | 0.60 | 0.51 | 0.24, 0.97 | 0.07 |
| Bilirubin >1.1 g/dl | 0.70 | 0.39, 1.25 | 0.23 | 0.82 | 0.42, 1.59 | 0.56 |
| Albumin <3.6 g/dl | 1.41 | 0.80, 2.48 | 0.23 | 1.62 | 0.81, 3.23 | 0.17 |
| Cirrhosis | 0.68 | 0.31, 1.48 | 0.33 | 0.84 | 0.35, 2.07 | 0.71 |
| Treatment experienced | 0.79 | 0.48, 1.31 | 0.36 | 0.81 | 0.45, 1.47 | 0.49 |
†
AOR: Adjusted odds ratio, by multivariable logistic regression modeling including all variables shown in the table.